Fears are that the new GlaxoSmithKline diabetes drug may not be substantially better than rivals in its class – according to diabetes news reports this morning. The experimental diabetic drug Syncria achieved comparable results to other GLP-1 medication, but nothing that raises it beyond these drugs .
The aim of the drug is to rival blockbuster Byetta ( Eli Lilly and Amylin ) and Victoza (Novo Nordisk), both type 2 diabetes treatments at different stages of release.
Citigroup analyst Peter Verdult was reportedly not impressed by the drug. He was cited as commenting: "In our view, Syncria is beginning to look like a me-too drug, assuming exenatide LAR (long-acting Byetta), Victoza and Roche and Ipsen's taspoglutide make it to market first."
There was reportedly a low absolute HbA1C reduction, and modest weight loss .
New Glaxo diabetes drug not overwhelming
Tue, 09 Jun 2009
Recommended links
Diabetes financeDiabetes forum
The big three diabetes signs and symptoms
Diabetes donate
Diabetes diagnosis in a new way
Salt influence on diabetes drugs
Glaxo launches new diabetes drug in US
No publicity by Glaxo about diabetes drug
Side effects of Glaxo drugs
Glaxo plays down diabetes drug study
Glaxo little affected by diabetes drug warning
Glaxo facing a lawsuit over diabetes drug
Glaxo resumes diabetes drug manufacture
GlaxoSmithKline short on drugs
Glaxo facing lawsuit over diabetes drug
GlaxoSmithKline see diabetes drug sales slump
Glaxo diabetes drug could come back
Diabetes drug impacts on Glaxo profit
Join us